バイオシミュレーション市場の規模、シェア、動向分析レポート:製品別(ソフトウェア、サービス)、用途別(医薬品開発、創薬)、エンドユーザー別、地域別、セグメント別予測、2022年〜2030年Biosimulation Market Size, Share & Trends Analysis Report By Product (Software, Services), By Application (Drug Development, Drug Discovery), By End Use, By Region, And Segment Forecasts, 2022 - 2030 バイオシミュレーション市場の成長と動向 グランドビューリサーチ社の最新レポートによると、世界のバイオシミュレーション市場規模は2030年までに99億5000万米ドルに達すると予想されています。同市場は... もっと見る
日本語のページは自動翻訳を利用し作成しています。
サマリー
バイオシミュレーション市場の成長と動向 目次Table of ContentsChapter 1 Methodology and Scope 1.1 Market Segmentation and Scope 1.1.1 segment scope 1.1.2 regional scope 1.1.3 Estimates and forecast timeline 1.2 Research Methodology 1.3 Information procurement 1.3.1 Purchased database: 1.3.2 GVR’s internal database 1.3.3 Secondary sources 1.3.4 Primary research 1.3.5 Details of primary research 1.4 Information or Data Analysis 1.4.1 Data analysis models 1.5 Market Formulation & Validation 1.6 Model Details 1.7 List of Secondary Sources 1.8 Objectives 1.8.1 Objective 1 1.8.2 Objective 2 1.8.3 Objective 3 1.8.4 Objective 4 Chapter 2 Executive Summary 2.1 Biosimulation Market Summary Chapter 3 Biosimulation Market Variables, Trends & Scope 3.1 Biosimulation Market Segmentation and Scope 3.2 Biosimulation Market Dynamics 3.2.1 Market driver analysis 3.2.2 Impact analysis 3.2.2.1 Increasing adoption of Physiologically Based Pharmacokinetic Modeling in the regulatory approval process of drugs 3.2.2.2 Growing number of relapse cases due to increasing drug resistance 3.2.2.3 Rising Technological advancements 3.2.2.4 Increasing need to reduce drug discovery and development costs 3.2.2.5 accelerating formulation development and saving costly studies 3.2.2.6 Increasing investments in the life sciences industry 3.2.2.7 Increasing use of personalized medicine 3.2.3 Market restraint analysis 3.2.4 Impact analysis 3.2.4.1 Lack of standardization 3.2.4.2 Shortage of skilled professionals 3.2.4.3 Intellectual property protection and public policy issues 3.3 Penetration and Growth Prospect Mapping, 2021 3.4 Pricing Analysis 3.5 Biosimulation Market Analysis Tools: Porters 3.5.1 bargaining power of Suppliers: Low 3.5.2 bargaining power of Buyers: Moderate 3.5.3 Therat of Substitutes: Low 3.5.4 Threat of New Entrants: High 3.5.5 Competitive Rivalry: High 3.6 SWOT Analysis by Factors (Political & Legal, Economic, and Technological) 3.6.1 Political/Legal Landscape 3.6.2 Economic Landscape 3.6.3 Technology Landscape Chapter 4 Biosimulation Market: Impact of COVID-19 4.1 Impact of Covid-19 on the Biosimulation Market 4.1.1 Current And Future Impact Analysis 4.1.2 Impact of covid-19 on market players 4.1.3 Disease Prevalence Analysis Chapter 5 Biosimulation Market: Segment Analysis, By Product, 2017 - 2030 (USD Million) 5.1 Definition and Scope 5.2 Product Market Share Analysis, 2021 & 2030 5.3 Biosimulation Market, by Product, 2017 - 2030 5.4 Software 5.4.1 software market, 2017 - 2030 (USD Million) 5.5 Services 5.5.1 Services market, 2017 - 2030 (USD Million) 5.5.2 In-house Services 5.5.2.1 In-house Services market, 2017 - 2030 (USD Million) 5.5.3 Contract Services 5.5.3.1 Contract Services market, 2017 - 2030 (USD Million) Chapter 6 Biosimulation Market: Segment Analysis, By Application, 2017 - 2030 (USD Million) 6.1 Definition and Scope 6.2 Application Market Share Analysis, 2021 & 2030 6.3 Biosimulation Market, by Application, 2017 - 2030 6.4 Drug Development 6.4.1 drug development market, 2017 - 2030 (USD Million) 6.5 Drug Discovery 6.5.1 Drug Discovery market, 2017 - 2030 (USD Million) 6.6 Others 6.6.1 Others market, 2017 - 2030 (USD Million) Chapter 7 Biosimulation Market: Segment Analysis, By End-use, 2017 - 2030 (USD Million) 7.1 Definition and Scope 7.2 End-use Market Share Analysis, 2021 & 2030 7.3 Global Biosimulation Market, by End-use, 2017 - 2030 7.4 Pharmaceutical & Biotechnology Companies 7.4.1 Pharmaceutical & biotechnology companies market, 2017 - 2030 (USD Million) 7.5 CROs 7.5.1 CROs market, 2017 - 2030 (USD million) 7.6 Regulatory Authorities 7.6.1 Regulatory authorities market, 2017 - 2030 (USD Million) 7.7 Academic Research Institutions 7.7.1 Academic research institutions market, 2017 - 2030 (USD million) Chapter 8 Biosimulation Market: Regional Market Analysis 2017 - 2030 (USD Million) 8.1 Definition & Scope 8.2 Regional Market Share Analysis, 2021 & 2030 8.3 Regional Market Snapshot 8.4 Market Size, & Forecasts, and Trend Analysis, 2017 - 2030 8.5 North America 8.5.1 North America Biosimulation Market Share Analysis, By Country, 2021 8.5.2 U.S. 8.5.2.1 U.S. Biosimulation Market, 2017 - 2030 (USD Million) 8.5.3 Canada 8.5.3.1 Canada Biosimulation Market, 2017 - 2030 (USD Million) 8.6 Europe 8.6.1 Europe Biosimulation Market Share Analysis, By Country, 2021 8.6.2 U.K. 8.6.2.1 U.K. Biosimulation Market, 2017 - 2030 (USD Million) 8.6.3 Germany 8.6.3.1 Germany Biosimulation Market, 2017 - 2030 (USD Million) 8.6.4 France 8.6.4.1 France Biosimulation Market, 2017 - 2030 (USD Million) 8.7 Asia Pacific 8.7.1 Asia Pacific Biosimulation Market Share Analysis, By Country, 2021 8.7.2 Japan 8.7.2.1 Japan Biosimulation Market, 2017 - 2030 (USD Million) 8.7.3 China 8.7.3.1 China Biosimulation Market, 2017 - 2030 (USD million) 8.7.4 India 8.7.4.1 India Biosimulation Market, 2017 - 2030 (USD Million) 8.8 Latin America 8.8.1 Latin America Biosimulation Market Share Analysis, By Country, 2021 8.8.2 Brazil 8.8.2.1 Brazil Biosimulation Market, 2017 - 2030 (USD Million) 8.8.3 Mexico 8.8.3.1 Mexico Biosimulation Market, 2017 - 2030 (USD Million) 8.9 MEA 8.9.1 MEA Biosimulation Market Share Analysis, By Country, 2021 8.9.2 South Africa 8.9.2.1 South Africa Biosimulation Market, 2017 - 2030 (USD Million) Chapter 9 Biosimulation Market - Competitive Analysis 9.1 Strategy Framework 9.2 Market Participant Categorization 9.3 Public Companies 9.3.1 Company market position analysis 9.3.2 Comparative analysis by product category 9.4 Private Companies 9.4.1 List of Private companies 9.4.2 List of Emerging companies in the Asia Pacific Region Chapter 10 Biosimulation Market - Company Profiles 10.1 Certara, USA 10.1.1 Company overview 10.1.2 Financial performance 10.1.3 Product benchmarking 10.1.4 Strategic initiatives 10.2 Simulations Plus 10.2.1 Company overview 10.2.2 Financial performance 10.2.3 Product benchmarking 10.2.4 Strategic initiatives 10.3 Dassault Systèmes 10.3.1 Company overview 10.3.2 Financial performance 10.3.3 Product benchmarking 10.3.4 Strategic initiatives 10.4 Schrödinger, Inc. 10.4.1 Company overview 10.4.2 Financial performance 10.4.3 Product benchmarking 10.4.4 Strategic initiatives 10.5 Advanced Chemistry Development 10.5.1 Company overview 10.5.2 Product benchmarking 10.5.3 Strategic initiatives 10.6 Chemical Computing Group ULC 10.6.1 Company overview 10.6.2 Financial performance 10.6.3 Product benchmarking 10.6.4 Strategic initiatives 10.7 Physiomics Plc 10.7.1 Company overview 10.7.2 Financial performance 10.7.3 Product benchmarking 10.7.4 Strategic initiatives 10.8 Rosa & Co. LLC 10.8.1 Company overview 10.8.2 Product benchmarking 10.8.3 Strategic initiatives 10.9 Biosimulation Consulting Inc. 10.9.1 Company overview 10.9.2 Financial performance 10.9.3 Service benchmarking 10.10 Genedata AG 10.10.1 Company overview 10.10.2 Financial performance 10.10.3 Product benchmarking 10.10.4 Strategic initiatives 10.11 Instem Group of Companies 10.11.1 Company overview 10.11.2 Financial performance 10.11.3 Product benchmarking 10.11.4 Strategic initiatives 10.12 PPD, Inc. 10.12.1 Company overview 10.12.2 Financial performance 10.12.3 Service benchmarking 10.12.4 Strategic initiatives 10.13 Yokogawa Insilico Biotechnology GmbH 10.13.1 Company overview 10.13.2 Product benchmarking 10.13.3 Strategic initiatives 10.14 Immunetrics 10.14.1 Company overview 10.14.2 Product benchmarking Chapter 11 KOL Commentary
SummaryBiosimulation Market Growth & Trends Table of ContentsTable of ContentsChapter 1 Methodology and Scope 1.1 Market Segmentation and Scope 1.1.1 segment scope 1.1.2 regional scope 1.1.3 Estimates and forecast timeline 1.2 Research Methodology 1.3 Information procurement 1.3.1 Purchased database: 1.3.2 GVR’s internal database 1.3.3 Secondary sources 1.3.4 Primary research 1.3.5 Details of primary research 1.4 Information or Data Analysis 1.4.1 Data analysis models 1.5 Market Formulation & Validation 1.6 Model Details 1.7 List of Secondary Sources 1.8 Objectives 1.8.1 Objective 1 1.8.2 Objective 2 1.8.3 Objective 3 1.8.4 Objective 4 Chapter 2 Executive Summary 2.1 Biosimulation Market Summary Chapter 3 Biosimulation Market Variables, Trends & Scope 3.1 Biosimulation Market Segmentation and Scope 3.2 Biosimulation Market Dynamics 3.2.1 Market driver analysis 3.2.2 Impact analysis 3.2.2.1 Increasing adoption of Physiologically Based Pharmacokinetic Modeling in the regulatory approval process of drugs 3.2.2.2 Growing number of relapse cases due to increasing drug resistance 3.2.2.3 Rising Technological advancements 3.2.2.4 Increasing need to reduce drug discovery and development costs 3.2.2.5 accelerating formulation development and saving costly studies 3.2.2.6 Increasing investments in the life sciences industry 3.2.2.7 Increasing use of personalized medicine 3.2.3 Market restraint analysis 3.2.4 Impact analysis 3.2.4.1 Lack of standardization 3.2.4.2 Shortage of skilled professionals 3.2.4.3 Intellectual property protection and public policy issues 3.3 Penetration and Growth Prospect Mapping, 2021 3.4 Pricing Analysis 3.5 Biosimulation Market Analysis Tools: Porters 3.5.1 bargaining power of Suppliers: Low 3.5.2 bargaining power of Buyers: Moderate 3.5.3 Therat of Substitutes: Low 3.5.4 Threat of New Entrants: High 3.5.5 Competitive Rivalry: High 3.6 SWOT Analysis by Factors (Political & Legal, Economic, and Technological) 3.6.1 Political/Legal Landscape 3.6.2 Economic Landscape 3.6.3 Technology Landscape Chapter 4 Biosimulation Market: Impact of COVID-19 4.1 Impact of Covid-19 on the Biosimulation Market 4.1.1 Current And Future Impact Analysis 4.1.2 Impact of covid-19 on market players 4.1.3 Disease Prevalence Analysis Chapter 5 Biosimulation Market: Segment Analysis, By Product, 2017 - 2030 (USD Million) 5.1 Definition and Scope 5.2 Product Market Share Analysis, 2021 & 2030 5.3 Biosimulation Market, by Product, 2017 - 2030 5.4 Software 5.4.1 software market, 2017 - 2030 (USD Million) 5.5 Services 5.5.1 Services market, 2017 - 2030 (USD Million) 5.5.2 In-house Services 5.5.2.1 In-house Services market, 2017 - 2030 (USD Million) 5.5.3 Contract Services 5.5.3.1 Contract Services market, 2017 - 2030 (USD Million) Chapter 6 Biosimulation Market: Segment Analysis, By Application, 2017 - 2030 (USD Million) 6.1 Definition and Scope 6.2 Application Market Share Analysis, 2021 & 2030 6.3 Biosimulation Market, by Application, 2017 - 2030 6.4 Drug Development 6.4.1 drug development market, 2017 - 2030 (USD Million) 6.5 Drug Discovery 6.5.1 Drug Discovery market, 2017 - 2030 (USD Million) 6.6 Others 6.6.1 Others market, 2017 - 2030 (USD Million) Chapter 7 Biosimulation Market: Segment Analysis, By End-use, 2017 - 2030 (USD Million) 7.1 Definition and Scope 7.2 End-use Market Share Analysis, 2021 & 2030 7.3 Global Biosimulation Market, by End-use, 2017 - 2030 7.4 Pharmaceutical & Biotechnology Companies 7.4.1 Pharmaceutical & biotechnology companies market, 2017 - 2030 (USD Million) 7.5 CROs 7.5.1 CROs market, 2017 - 2030 (USD million) 7.6 Regulatory Authorities 7.6.1 Regulatory authorities market, 2017 - 2030 (USD Million) 7.7 Academic Research Institutions 7.7.1 Academic research institutions market, 2017 - 2030 (USD million) Chapter 8 Biosimulation Market: Regional Market Analysis 2017 - 2030 (USD Million) 8.1 Definition & Scope 8.2 Regional Market Share Analysis, 2021 & 2030 8.3 Regional Market Snapshot 8.4 Market Size, & Forecasts, and Trend Analysis, 2017 - 2030 8.5 North America 8.5.1 North America Biosimulation Market Share Analysis, By Country, 2021 8.5.2 U.S. 8.5.2.1 U.S. Biosimulation Market, 2017 - 2030 (USD Million) 8.5.3 Canada 8.5.3.1 Canada Biosimulation Market, 2017 - 2030 (USD Million) 8.6 Europe 8.6.1 Europe Biosimulation Market Share Analysis, By Country, 2021 8.6.2 U.K. 8.6.2.1 U.K. Biosimulation Market, 2017 - 2030 (USD Million) 8.6.3 Germany 8.6.3.1 Germany Biosimulation Market, 2017 - 2030 (USD Million) 8.6.4 France 8.6.4.1 France Biosimulation Market, 2017 - 2030 (USD Million) 8.7 Asia Pacific 8.7.1 Asia Pacific Biosimulation Market Share Analysis, By Country, 2021 8.7.2 Japan 8.7.2.1 Japan Biosimulation Market, 2017 - 2030 (USD Million) 8.7.3 China 8.7.3.1 China Biosimulation Market, 2017 - 2030 (USD million) 8.7.4 India 8.7.4.1 India Biosimulation Market, 2017 - 2030 (USD Million) 8.8 Latin America 8.8.1 Latin America Biosimulation Market Share Analysis, By Country, 2021 8.8.2 Brazil 8.8.2.1 Brazil Biosimulation Market, 2017 - 2030 (USD Million) 8.8.3 Mexico 8.8.3.1 Mexico Biosimulation Market, 2017 - 2030 (USD Million) 8.9 MEA 8.9.1 MEA Biosimulation Market Share Analysis, By Country, 2021 8.9.2 South Africa 8.9.2.1 South Africa Biosimulation Market, 2017 - 2030 (USD Million) Chapter 9 Biosimulation Market - Competitive Analysis 9.1 Strategy Framework 9.2 Market Participant Categorization 9.3 Public Companies 9.3.1 Company market position analysis 9.3.2 Comparative analysis by product category 9.4 Private Companies 9.4.1 List of Private companies 9.4.2 List of Emerging companies in the Asia Pacific Region Chapter 10 Biosimulation Market - Company Profiles 10.1 Certara, USA 10.1.1 Company overview 10.1.2 Financial performance 10.1.3 Product benchmarking 10.1.4 Strategic initiatives 10.2 Simulations Plus 10.2.1 Company overview 10.2.2 Financial performance 10.2.3 Product benchmarking 10.2.4 Strategic initiatives 10.3 Dassault Systèmes 10.3.1 Company overview 10.3.2 Financial performance 10.3.3 Product benchmarking 10.3.4 Strategic initiatives 10.4 Schrödinger, Inc. 10.4.1 Company overview 10.4.2 Financial performance 10.4.3 Product benchmarking 10.4.4 Strategic initiatives 10.5 Advanced Chemistry Development 10.5.1 Company overview 10.5.2 Product benchmarking 10.5.3 Strategic initiatives 10.6 Chemical Computing Group ULC 10.6.1 Company overview 10.6.2 Financial performance 10.6.3 Product benchmarking 10.6.4 Strategic initiatives 10.7 Physiomics Plc 10.7.1 Company overview 10.7.2 Financial performance 10.7.3 Product benchmarking 10.7.4 Strategic initiatives 10.8 Rosa & Co. LLC 10.8.1 Company overview 10.8.2 Product benchmarking 10.8.3 Strategic initiatives 10.9 Biosimulation Consulting Inc. 10.9.1 Company overview 10.9.2 Financial performance 10.9.3 Service benchmarking 10.10 Genedata AG 10.10.1 Company overview 10.10.2 Financial performance 10.10.3 Product benchmarking 10.10.4 Strategic initiatives 10.11 Instem Group of Companies 10.11.1 Company overview 10.11.2 Financial performance 10.11.3 Product benchmarking 10.11.4 Strategic initiatives 10.12 PPD, Inc. 10.12.1 Company overview 10.12.2 Financial performance 10.12.3 Service benchmarking 10.12.4 Strategic initiatives 10.13 Yokogawa Insilico Biotechnology GmbH 10.13.1 Company overview 10.13.2 Product benchmarking 10.13.3 Strategic initiatives 10.14 Immunetrics 10.14.1 Company overview 10.14.2 Product benchmarking Chapter 11 KOL Commentary
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(薬学的薬物)の最新刊レポートGrand View Research社のその他分野での最新刊レポート
本レポートと同じKEY WORD(drug)の最新刊レポート
よくあるご質問Grand View Research社はどのような調査会社ですか?グランドビューリサーチ(Grand View Research)は通信技術、化学品、材料、ヘルスケア、エネルギーなど広範な市場を対象にした調査報告書を出版しています。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/21 10:26 156.13 円 165.08 円 200.38 円 |